A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
一项1B/2期开放标签,多中心研究,以评估有或没有其他抗癌研究剂的Raludotatug deruxtecan的安全性和功效
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.
Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:
- Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
- Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread
Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
研究概览
地位
条件
详细说明
This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Toll Free Number
- 电话号码:1-888-577-8839
- 邮箱:Trialsites@msd.com
学习地点
-
-
-
Haifa、以色列、3109601
- 招聘中
- Rambam Health Care Campus ( Site 0202)
-
接触:
- Study Coordinator
- 电话号码:972-4-7776234
-
Jerusalem、以色列、9103102
- 招聘中
- Shaare Zedek Medical Center ( Site 0201)
-
接触:
- Study Coordinator
- 电话号码:+972-(0)2-6555424
-
Petah Tikva、以色列、4941492
- 招聘中
- Rabin Medical Center ( Site 0203)
-
接触:
- Study Coordinator
- 电话号码:+97239378076
-
Ramat Gan、以色列、5265601
- 招聘中
- Sheba Medical Center ( Site 0200)
-
接触:
- Study Coordinator
- 电话号码:972-3-5304498
-
-
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- Princess Margaret Cancer Centre ( Site 0101)
-
接触:
- Study Coordinator
- 电话号码:416-946-2818
-
-
Quebec
-
Montreal、Quebec、加拿大、H4A 3J1
- 招聘中
- McGill University Health Centre ( Site 0100)
-
接触:
- Study Coordinator
- 电话号码:514-934-1934x31975
-
Montreal、Quebec、加拿大、H2X 0A9
- 招聘中
- Centre Hospitalier de l'Université de Montréal ( Site 0102)
-
接触:
- Study Coordinator
- 电话号码:514-890-8000
-
-
-
-
-
Taipei、台湾、100225
- 招聘中
- National Taiwan University Hospital ( Site 3001)
-
接触:
- Study Coordinator
- 电话号码:+886223123456
-
Taoyuan、台湾、33305
- 招聘中
- Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
-
接触:
- Study Coordinator
- 电话号码:+88633281200
-
-
-
-
Victoria
-
St Albans、Victoria、澳大利亚、3021
- 招聘中
- Western Health-Sunshine & Footscray Hospitals ( Site 1002)
-
接触:
- Study Coordinator
- 电话号码:+61402775432
-
-
-
-
-
Sankt Gallen、瑞士、9000
- 招聘中
- HOCH Health Ostschweiz ( Site 0801)
-
接触:
- Study Coordinator
- 电话号码:+41714941111
-
-
Canton of Basel-City
-
Basel、Canton of Basel-City、瑞士、4031
- 招聘中
- University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
-
接触:
- Study Coordinator
- 电话号码:+41613284214
-
-
Canton of Vaud
-
Lausanne、Canton of Vaud、瑞士、1011
- 招聘中
- CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
-
接触:
- Study Coordinator
- 电话号码:+41795567362
-
-
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 招聘中
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
-
接触:
- Study Coordinator
- 电话号码:203-785-2404
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- 招聘中
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
-
接触:
- Study Coordinator
- 电话号码:502-562-3429
-
-
Louisiana
-
Shreveport、Louisiana、美国、71103
- 招聘中
- TRIALS 365 ( Site 0020)
-
接触:
- Study Coordinator
- 电话号码:318-408-1198
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute ( Site 0015)
-
接触:
- Study Coordinator
- 电话号码:877-338-7425
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center ( Site 0003)
-
接触:
- Study Coordinator
- 电话号码:212-639-2000
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- OU Health University of Oklahoma Medical Center ( Site 7000)
-
接触:
- Study Coordinator
- 电话号码:405-271-1112
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- Texas Oncology - DFW ( Site 8000)
-
接触:
- Study Coordinator
- 电话号码:615-329-7430
-
Houston、Texas、美国、77030
- 完全的
- Houston Methodist Hospital ( Site 0010)
-
-
Utah
-
West Valley City、Utah、美国、84119
- 招聘中
- START Mountain Region ( Site 0008)
-
接触:
- Study Coordinator
- 电话号码:801-907-4750
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- University of Virginia Health System ( Site 0011)
-
接触:
- Study Coordinator
- 电话号码:434-924-9333
-
-
-
-
-
Manchester、英国、M20 4BX
- 招聘中
- The Christie NHS Foundation Trust ( Site 0405)
-
接触:
- Study Coordinator
- 电话号码:+441619187689
-
-
East Sussex
-
Brighton、East Sussex、英国、BN2 1ES
- 招聘中
- University Hospitals Sussex NHS Foundation Trust ( Site 0404)
-
接触:
- Study Coordinator
- 电话号码:+44 01273 696 955
-
-
England
-
Fulham、England、英国、SW3 6JJ
- 招聘中
- Royal Marsden Hospital ( Site 0402)
-
接触:
- Study Coordinator
- 电话号码:+442078118084
-
Sutton、England、英国、SM2 5PT
- 招聘中
- The Royal Marsden NHS Foundation Trust. ( Site 0403)
-
接触:
- Study Coordinator
- 电话号码:+442078118084
-
-
London, City of
-
London、London, City of、英国、E1 1RD
- 招聘中
- Barts Health NHS Trust ( Site 0401)
-
接触:
- Study Coordinator
- 电话号码:020 7377 7000
-
London、London, City of、英国、SE1 3SS
- 招聘中
- Guy s & St Thomas NHS Foundation Trust ( Site 0400)
-
接触:
- Study Coordinator
- 电话号码:+44 020 7188 7188
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
-
接触:
- Study Coordinator
- 电话号码:+349325434528607
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre ( Site 0304)
-
接触:
- Study Coordinator
- 电话号码:+34913908626
-
Madrid、西班牙、28040
- 招聘中
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
-
接触:
- Study Coordinator
- 电话号码:34915504800 x2805
-
Málaga、西班牙、29010
- 招聘中
- Hospital Universitario Virgen de la Victoria ( Site 0306)
-
接触:
- Study Coordinator
- 电话号码:+34951032508
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、西班牙、08908
- 招聘中
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
-
接触:
- Study Coordinator
- 电话号码:+34932607744
-
-
Madrid
-
Majadhonda、Madrid、西班牙、28222
- 招聘中
- HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
-
接触:
- Study Coordinator
- 电话号码:+34 911917358
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、西班牙、28027
- 招聘中
- Clinica Universidad de Navarra ( Site 0301)
-
接触:
- Study Coordinator
- 电话号码:+349135319207513
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、西班牙、46014
- 招聘中
- Hospital General Universitario de Valencia ( Site 0305)
-
接触:
- Study Coordinator
- 电话号码:+34 963187527
-
-
-
-
-
Seoul、韩国、03080
- 招聘中
- Seoul National University Hospital ( Site 2000)
-
接触:
- Study Coordinator
- 电话号码:+82220723511
-
Seoul、韩国、03722
- 招聘中
- Severance Hospital, Yonsei University Health System ( Site 2002)
-
接触:
- Study Coordinator
- 电话号码:+82222282230
-
Seoul、韩国、05505
- 招聘中
- Asan Medical Center ( Site 2003)
-
接触:
- Study Coordinator
- 电话号码:+82230103646
-
Seoul、韩国、06351
- 招聘中
- Samsung Medical Center ( Site 2001)
-
接触:
- Study Coordinator
- 电话号码:82234101382
-
-
Kyonggi-do
-
Goyang-si、Kyonggi-do、韩国、10408
- 招聘中
- National Cancer Center ( Site 2004)
-
接触:
- Study Coordinator
- 电话号码:82319201760
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
- Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
- Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
- Has provided tumor tissue for biomarker research (all cohorts)
- Has an Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
- Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant
Exclusion Criteria:
- Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
- Has ≥Grade 2 peripheral neuropathy
- Has received prior treatment with cadherin-6-targeted agents
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Receives chronic steroid treatment
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)
Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
实验性的:Cohort A-1 Arm 2 (R-DXd + Paclitaxel)
Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
实验性的:Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)
Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
实验性的:Cohort B-1 (R-DXd + Bevacizumab)
Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
其他名称:
|
|
实验性的:Cohort B-2 (R-DXd RP2D + Bevacizumab)
Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
其他名称:
|
|
实验性的:Cohort C-1 (R-DXd + Pembrolizumab)
Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
实验性的:Cohort D (R-DXd +/- Bevacizumab)
Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
其他名称:
|
|
实验性的:Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
其他名称:
|
|
实验性的:Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
其他名称:
|
|
有源比较器:Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)
Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV injection on days 1 and 8 of each 3-week Cycle IV injection administered on Day 1 of each 4-week cycle
其他名称:
|
|
实验性的:Cohort E-1 (R-DXd + MK-2010)
Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle |
|
实验性的:Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)
Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles). |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
实验性的:Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)
Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
实验性的:Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)
Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease. |
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle.
其他名称:
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
大体时间:Up to 21 days
|
DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
大体时间:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported. |
Up to approximately 3 years
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
大体时间:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Objective Response Rate (ORR)
大体时间:Up to approximately 3 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
大体时间:Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1: Objective Response Rate (ORR)
大体时间:Up to approximately 3 years
|
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR). |
Up to approximately 3 years
|
|
Part 2: Duration of Response (DOR)
大体时间:Up to approximately 3 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
大体时间:Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Overall Survival (OS)
大体时间:Up to approximately 5 years
|
OS is defined as the time from the first dose of study treatment to death due to any cause. |
Up to approximately 5 years
|
|
Part 2: Number of Participants with One or More AEs
大体时间:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
大体时间:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 5909-003
- MK-5909-003 (其他标识符:MSD)
- U1111-1308-2821 (注册表标识符:UTN)
- 2024-514674-47-00 (注册表标识符:EU CT)
- REJOICE-Ovarian02 (其他标识符:MSD)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.